典型文献
Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy
文献摘要：
Despite the advancement of treatments, adults with relapsed/refractory (R/R) B-lineage acute lym-phoblastic leukemia (B-ALL) have poor prognosis, with an expected five-year overall survival (OS) rate of 10％?20％(Nguyen et al., 2008;Oriol et al., 2010). Extramedullary relapse of B-ALL is regarded as a high-risk factor generally associated with poor survival, occurring in about 15％to 20％of all relapsed patients (Ding et al., 2017; Sun et al., 2018). The central nervous system (CNS) and the testes are the most common sites of extramedullary relapse of B-ALL. In addition, extramedullary leukemia can appear in the skin, eyes, breasts, bones, muscles, and abdominal organs. The prognosis of relapsed extramedullary B-ALL after allogeneic hematopoietic stem cell trans-plantation (allo-HSCT) is extremely poor (Spyridonidis et al., 2012; Dahlberg et al., 2019). Conventional chemotherapy or radiation is often ineffective in such patients. At present, there are no optimal treatment strategies for treating extramedullary leukemia after allo-HSCT.
文献关键词：
中图分类号：
作者姓名：
Delin KONG;Tingting YANG;Jia GENG;Ruirui JING;Qiqi ZHANG;Guoqing WEI;He HUANG;Yongxian HU
作者机构：
Bone Marrow Transplantation Center,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Liangzhu Laboratory,Zhejiang University Medical Center,Hangzhou 311121,China;Institute of Hematology,Zhejiang University,Hangzhou 310058,China;Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy,Hangzhou 310058,China;Department of Radiology,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China
引用格式：
[1]Delin KONG;Tingting YANG;Jia GENG;Ruirui JING;Qiqi ZHANG;Guoqing WEI;He HUANG;Yongxian HU-.Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy)[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2022(10):876-880
A类：
phoblastic,Oriol,Extramedullary,Spyridonidis,Dahlberg
B类：
Secondary,donor,derived,CD19,CAR,safe,efficacious,acute,lymphoblastic,leukemia,extramedullary,after,first,autologous,Despite,advancement,treatments,adults,relapsed,refractory,lineage,ALL,have,poor,prognosis,expected,five,year,overall,survival,OS,Nguyen,regarded,high,risk,generally,associated,occurring,about,patients,Ding,Sun,central,nervous,system,CNS,testes,are,most,common,sites,In,addition,can,appear,skin,eyes,breasts,bones,muscles,abdominal,organs,allogeneic,hematopoietic,cell,trans,plantation,HSCT,extremely,Conventional,chemotherapy,radiation,often,ineffective,such,At,present,there,optimal,strategies,treating
AB值：
0.523113
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
